Tackling dipeptidyl peptidase Ⅳ in neurological disorders
Ghaith Al-Badri
Gian Marco Leggio
Giuseppe Musumeci
Rubina Marzagalli
Filippo Drago
Alessandro Castorina
摘要：Dipeptidyl peptidase Ⅳ (DPP-Ⅳ) is a serine protease best known for its role in inactivating glucagon-like peptide-1 (GLP-1),pituitary adenylate cyclase-activating polypeptide (PACAP) and glucose-dependent insulinotropic peptide (GIP),three stimulators of pancreatic insulin secretion with beneficial effects on glucose disposal.Owing to the relationship between DPP-Ⅳ and these peptides,inhibition of DPP-Ⅳ enzyme activity is considered as an attractive treatment option for diabetic patients.Nonetheless,increasing studies support the idea that DPP-Ⅳ might also be involved in the development of neurological disorders with a neuroinflammatory component,potentially through its non-incretin activities on immune cells.In this review article,we aim at highlighting recent literature describing the therapeutic value of DPP-Ⅳ inhibitors for the treatment of such neurological conditions.Finally,we will illustrate some of the promising results obtained using berberine,a plant extract with potent inhibitory activity on DPP-Ⅳ.
机标关键词：
论文发表日期：2018-01-01
在线出版日期：2025-08-15（本平台首次上网日期，不代表文献的发表时间）
页数：9( 26-34 )
英文信息